Overview

This trial is active, not recruiting.

Condition multiple myeloma
Treatment pcv13
Sponsor H. Lee Moffitt Cancer Center and Research Institute
Start date February 2013
End date February 2015
Trial size 8 participants
Trial identifier NCT01852591, MCC-16727

Summary

There is no study hypothesis. The purpose of this study is to see if the Pneumococcal conjugate vaccine (PCV13), when administered before and early after an autologous peripheral stem cell transplant will induce an immune response.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Endpoint classification efficacy study
Intervention model single group assignment
Masking open label
Arm
(Experimental)
Pneumococcal conjugate vaccine (PCV13, 0.5ml) 3 to 30 days prior to transplant and then again at 7-10 and 21-24 days after transplant
pcv13 Prevnar

Primary Outcomes

Measure
Number of Participants with Immune Response
time frame: 180 days

Eligibility Criteria

Male or female participants at least 18 years old.

Inclusion Criteria: - Patients with confirmed multiple myeloma - Eligible for treatment with high dose melphalan based regimen and autologous peripheral stem cell transplant Exclusion Criteria: - Pregnant or lactating woman, as evaluated by serum testing within 24 hours of administration of the first vaccine - HIV infection confirmed by nucleic acid testing (NAT), as evaluated during pre transplant testing - Common variable immunodeficiency or other inherited systemic immunodeficiency syndrome - Active central nervous system (CNS) malignancy - Prior malignancy within 5 years of enrollment excluding non-melanoma skin cancer or cervical carcinoma after curative resection, not requiring chemotherapy. - History of severe allergy (e.g., anaphylaxis) to any component of pneumococcal conjugate vaccine 7 (PCV7), PCV13, or any diphtheria-toxoid containing vaccine. - Inclusion on a separate trial in which patients may be randomized or otherwise started on maintenance chemotherapies within the first 3 months of autologous transplantation - Patients with significant psychiatric illness likely to affect compliance, as determined by the treating physician - Active or uncontrolled infection - Diffusing lung capacity oxygenation (DLCO) <50 % - Left ventricular ejection fraction (LVEF) <40% - Bilirubin >2

Additional Information

Official title Exploration of Immune Response to Pneumococcal Conjugate Vaccine (PCV13) Administered Before and Early After Autologous Peripheral Stem Cell Transplant (Auto-PSCT) in Patients With Multiple Myeloma
Principal investigator Frederick L Locke, MD
Description This is a pilot study to determine the safety of PCV13 administered to patients with myeloma before and at +7-10 days and +21-24 days after autologous hematopoietic stem cell transplant; and,to quantify the immune response induced by PCV13 vaccination in patients with myeloma when administered before and early after autologous PSCT.
Trial information was received from ClinicalTrials.gov and was last updated in December 2015.
Information provided to ClinicalTrials.gov by H. Lee Moffitt Cancer Center and Research Institute.